293 related articles for article (PubMed ID: 21612688)
1. [Alternative splicing of vascular endothelial growth factor A and ocular neovascularization].
Fan SJ; He SZ
Zhonghua Yan Ke Za Zhi; 2011 Apr; 47(4):373-7. PubMed ID: 21612688
[TBL] [Abstract][Full Text] [Related]
2. Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor.
Perrin RM; Konopatskaya O; Qiu Y; Harper S; Bates DO; Churchill AJ
Diabetologia; 2005 Nov; 48(11):2422-7. PubMed ID: 16193288
[TBL] [Abstract][Full Text] [Related]
3. Alternative splicing in angiogenesis: the vascular endothelial growth factor paradigm.
Ladomery MR; Harper SJ; Bates DO
Cancer Lett; 2007 May; 249(2):133-42. PubMed ID: 17027147
[TBL] [Abstract][Full Text] [Related]
4. VEGF165b, an endogenous C-terminal splice variant of VEGF, inhibits retinal neovascularization in mice.
Konopatskaya O; Churchill AJ; Harper SJ; Bates DO; Gardiner TA
Mol Vis; 2006 May; 12():626-32. PubMed ID: 16735996
[TBL] [Abstract][Full Text] [Related]
5. Splicing factor polymorphisms, the control of VEGF isoforms and association with angiogenic eye disease.
Carter JG; Cherry J; Williams K; Turner S; Bates DO; Churchill AJ
Curr Eye Res; 2011 Apr; 36(4):328-35. PubMed ID: 21309690
[TBL] [Abstract][Full Text] [Related]
6. [Diabetic retinopathy--the mechanisms of the ocular neovascularization and the development of anti-angiogenic drugs].
Kuroki M; Kawakami M
Nihon Rinsho; 1999 Mar; 57(3):584-9. PubMed ID: 10199138
[TBL] [Abstract][Full Text] [Related]
7. Angiopoietin modulation of vascular endothelial growth factor: Effects on retinal endothelial cell permeability.
Peters S; Cree IA; Alexander R; Turowski P; Ockrim Z; Patel J; Boyd SR; Joussen AM; Ziemssen F; Hykin PG; Moss SE
Cytokine; 2007 Nov; 40(2):144-50. PubMed ID: 17959386
[TBL] [Abstract][Full Text] [Related]
8. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.
Aiello LP; Avery RL; Arrigg PG; Keyt BA; Jampel HD; Shah ST; Pasquale LR; Thieme H; Iwamoto MA; Park JE
N Engl J Med; 1994 Dec; 331(22):1480-7. PubMed ID: 7526212
[TBL] [Abstract][Full Text] [Related]
9. [The role of vascular endothelial growth factor in angiogenesis and diabetic retinopathy].
Valiatti FB; Crispim D; Benfica C; Valiatti BB; Kramer CK; Canani LH
Arq Bras Endocrinol Metabol; 2011 Mar; 55(2):106-13. PubMed ID: 21584427
[TBL] [Abstract][Full Text] [Related]
10. Role of the vascular endothelial growth factor isoforms in retinal angiogenesis and DiGeorge syndrome.
Stalmans I
Verh K Acad Geneeskd Belg; 2005; 67(4):229-76. PubMed ID: 16334858
[TBL] [Abstract][Full Text] [Related]
11. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy.
Watanabe D; Suzuma K; Matsui S; Kurimoto M; Kiryu J; Kita M; Suzuma I; Ohashi H; Ojima T; Murakami T; Kobayashi T; Masuda S; Nagao M; Yoshimura N; Takagi H
N Engl J Med; 2005 Aug; 353(8):782-92. PubMed ID: 16120858
[TBL] [Abstract][Full Text] [Related]
12. Different expression of vascular endothelial growth factor and pigment epithelium-derived factor between diabetic and non-diabetic epiretinal membranes.
Nam DH; Oh J; Roh JH; Huh K
Ophthalmologica; 2009; 223(3):188-91. PubMed ID: 19182495
[TBL] [Abstract][Full Text] [Related]
13. [VEGF in age-related macular degeneration. Part I. Physiologic and pathologic role of VEGF].
Wylegała E; Teper SJ
Klin Oczna; 2007; 109(1-3):94-6. PubMed ID: 17687924
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy.
Amin RH; Frank RN; Kennedy A; Eliott D; Puklin JE; Abrams GW
Invest Ophthalmol Vis Sci; 1997 Jan; 38(1):36-47. PubMed ID: 9008628
[TBL] [Abstract][Full Text] [Related]
15. Role of vascular endothelial growth factor in ocular angiogenesis.
Shams N; Ianchulev T
Ophthalmol Clin North Am; 2006 Sep; 19(3):335-44. PubMed ID: 16935208
[TBL] [Abstract][Full Text] [Related]
16. Expression of stromal cell-derived factor-1 in diabetic retinopathy.
Chen LY; Zhuo YH; Li YH; Huang XH; Zhang JL; Li SY; Wang XG; Lü L
Chin Med J (Engl); 2010 Apr; 123(8):984-8. PubMed ID: 20497701
[TBL] [Abstract][Full Text] [Related]
17. The transcription factor E2F1 and the SR protein SC35 control the ratio of pro-angiogenic versus antiangiogenic isoforms of vascular endothelial growth factor-A to inhibit neovascularization in vivo.
Merdzhanova G; Gout S; Keramidas M; Edmond V; Coll JL; Brambilla C; Brambilla E; Gazzeri S; Eymin B
Oncogene; 2010 Sep; 29(39):5392-403. PubMed ID: 20639906
[TBL] [Abstract][Full Text] [Related]
18. Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration.
Ciulla TA; Rosenfeld PJ
Curr Opin Ophthalmol; 2009 May; 20(3):166-74. PubMed ID: 19381089
[TBL] [Abstract][Full Text] [Related]
19. Pigment epithelium-derived factor downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGF-VEGF receptor 2 binding in diabetic retinopathy.
Zhang SX; Wang JJ; Gao G; Parke K; Ma JX
J Mol Endocrinol; 2006 Aug; 37(1):1-12. PubMed ID: 16901919
[TBL] [Abstract][Full Text] [Related]
20. Anti-angiogenic effects of ribonucleic acid interference targeting vascular endothelial growth factor and hypoxia-inducible factor-1alpha.
Forooghian F; Das B
Am J Ophthalmol; 2007 Nov; 144(5):761-8. PubMed ID: 17869204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
